EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response

Anjali T Owens iD, Milind Desai iD, Matthew T Wheeler iD, Anna Rodonski, Samira Merali iD, Amy J Sehnert iD, Sara Saberi iD

Journal of the American Heart Association · 03.09.2024 · 13 (17)

DOI: 10.1161/jaha.124.033767 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the American Heart Association, erschienen am 03.09.2024. Verfasst von Anjali T Owens und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Pennsylvania Perelman School of Medicine Philadelphia PA USA. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mavacamten is the first and only cardiac myosin inhibitor approved in 5 continents for the treatment of adults with symptomatic New York Heart Association class II and III obstructive hypertrophic cardiomyopathy. An evidence‐based rationale was used to develop individualized mavacamten dosing, guided by commonly used clinical parameters. Echocardiography is recommended as part of routine clinical assessment of patients with hypertrophic cardiomyopathy, and left ventricular (LV) outflow tract gradient and LV ejection fraction are parameters that can be readily assessed and monitored by echocardiography. Therefore, an echocardiography‐based, clinically guided dose‐titration strategy was developed to optimize patient benefit from mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy while minimizing the risk of LV ejection fraction reduction. Results from clinical trials paired with extensive modeling and simulation analyses support a dose‐titration and monitoring strategy based on serial echocardiographic measures of Valsalva LV outflow tract gradient and LV ejection fraction. This dosing approach allows for the identification of the lowest individualized mavacamten dose and exposure required to provide improvements in LV outflow tract obstruction, functional capacity, and symptoms. Mavacamten is primarily metabolized by CYP2C19 (cytochrome P450 2C19), and CYP2C19 metabolizer phenotype has an effect on mavacamten exposure. Therefore, this approach has also been demonstrated to provide a favorable safety profile irrespective of patients' CYP2C19 metabolizer status. The dose‐titration strategy includes additional considerations for the potential onset of systolic dysfunction in the context of intercurrent illness, and for the potential of drug–drug interactions with inhibitors and substrates of cytochrome P450 enzymes. This posology is reflected in the mavacamten US prescribing information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicHumansVentricular Function, LeftStroke VolumeTreatment OutcomeCytochrome P-450 CYP2C19UracilEchocardiographyDose-Response Relationship, DrugBenzylamines

Stichwörter der Autor:innen

echocardiogramindividualized dosingleft ventricular ejection fractionleft ventricular outflow tract gradientmavacamtenobstructive hypertrophic cardiomyopathy

Substanzen

MYK-461Cytochrome P-450 CYP2C19UracilCYP2C19 protein, humanBenzylamines

Autor:innen und Institutionen

  • University of Pennsylvania Perelman School of Medicine Philadelphia PA USA.
  • Heart, Vascular, and Thoracic Institute Cleveland Clinic Cleveland OH USA.
  • Division of Cardiovascular Medicine Stanford University School of Medicine Stanford CA USA.
  • Ascension Saint Thomas Heart West Nashville TN USA.
  • Bristol Myers Squibb Princeton NJ USA.
  • Division of Cardiovascular Medicine University of Michigan Ann Arbor MI USA.

ORCID-Profile: Anjali T Owens, Milind Desai, Matthew T Wheeler, Samira Merali, Amy J Sehnert, Sara Saberi

Zitieren

APA

Owens, A. T., Desai, M., Wheeler, M. T., Rodonski, A., Merali, S., Sehnert, A. J., & Saberi, S. (2024). Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response. Journal of the American Heart Association, 13(17). https://doi.org/10.1161/jaha.124.033767

Vancouver

Owens AT, Desai M, Wheeler MT, Rodonski A, Merali S, Sehnert AJ, et al. Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response. Journal of the American Heart Association. 2024;13(17). doi:10.1161/jaha.124.033767

BibTeX
@article{Owens2024,
  author = {Owens, Anjali T and Desai, Milind and Wheeler, Matthew T and Rodonski, Anna and Merali, Samira and Sehnert, Amy J and Saberi, Sara},
  title = {Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response},
  journal = {Journal of the American Heart Association},
  year = {2024},
  volume = {13},
  number = {17},
  doi = {10.1161/jaha.124.033767}
}
Kostenlos starten →